Cell Therapy Applications
-
Cell Therapy Development Workflow
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
By Berkeley Lights, Inc. based in Emeryville, CALIFORNIA (USA).
-
Drug Dolution for Gastric Cancer
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
By Ascelia Pharma AB based in Malmö, SWEDEN.
-
Cell Line Development Workflow
The new standard for quality, capacity, and speed. Deliver the best cell lines. Set your IND up for success by getting FDA-accepted monoclonality assurance in just ...
By Berkeley Lights, Inc. based in Emeryville, CALIFORNIA (USA).
-
Therapy Discogenic Cell for Degenerative Disc Disease
Degenerative disc disease is a chronic and progressive condition that is characterized by inflammation and breakdown of tissue within the intervertebral disc. Located between the vertebral bones in the spine, the intervertebral disc acts like a pillow to cushion and evenly distribute pressure across the vertebrae. Each disc is comprised of an outer fibrous ring, the annulus fibrosus, which surrounds an inner gel-like center, the nucleus pulposus. ...
By DiscGenics, Inc. based in Salt Lake City, UTAH (USA).
-
Gene therapies solutions for cell therapy sector
Absence of a means for affordable and effective cell engineering hinders the commercialization of these advanced treatments. CellFE’s technology can get life-saving therapies to the patient at lower cost, with shorter manufacturing time, and higher retention of inherent ...
By CellFE based in San Carlos, CALIFORNIA (USA).
-
Safety & efficacy testing solutions for cellular therapies areas
The key FDA’s and EMA’s biosafety concerns (1,2) are the potential for cell based tumorigenicity, immunogenicity, infectious disease, and or genetic modification. Cellular therapies are aimed at specific disease types and to proliferate and differentiate into the desired cell type without causing unnecessary and potentially dangerous proliferation into cancer cells or unwanted immunogenicity causing damage in surrounding ...
By Alcyomics Ltd. based in Newcastle Upon Tyne, UNITED KINGDOM.
-
Focal Molography Solution for Drug Screening
Real-time and label-free characterization of drug candidates in living ...
By lino Biotech AG based in Zurich, SWITZERLAND.
-
Biocontaminants
The manufacture of biopharmaceutical agents such as therapeutic monoclonal antibodies, vaccines and cell-based therapies like CAR-T cells require the highest quality control against the contamination of adventitious agents. These pathogens can enter the manufacturing process at multiple stages and impact yield and safety. Current methods for detection of adventitious agents are expensive, lack sensitivity and have long turn around times to results. Moreover, many of the current adventitious agent testing methods ...
By AccuGenomics, Inc. based in Wilmington, NORTH CAROLINA (USA).
-
Excitation-Contraction-Energy (ECE) Coupling Analysis for Cardiac Physiology
An electrical stimulation, i.e., action potential initiates cardiac contraction. Intracellular Ca2+-transient couples action potential and cardiac contraction. Cardiac contraction is also coupled to mitochondria that replenish energy (i.e., ATP) and recycle metabolites (ADP and Pi). InvivoSciences analyzes all those parameters to determine drug-induced or genetically driven changes in ECE ...
By InvivoSciences, Inc. (IVS) based in Madison, WISCONSIN (USA).
-
IGX Platform Software for Immuno-Oncology
Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...
By Enpicom B.V. based in s-Hertogenbosch, NETHERLANDS.
-
Focal Molography Solution for Bioprocess
Fast at-line determination of product quality and biological relevant status information on process ...
By lino Biotech AG based in Zurich, SWITZERLAND.
-
Albumin focused biotechnology solutions for cell therapy sector
In cell therapy, the source and quality of albumin has proven important for both performance and regulatory purposes. Albumedix' recombinant human albumin products are used in a range of cell therapy media and products offering increased viability, consistency and ...
By Albumedix Ltd. based in Nottingham, UNITED KINGDOM.
-
NK-cell Therapy - Ushering in the Future of NK-cell Therapy
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...
By Kiadis Pharma NV based in Amsterdam, NETHERLANDS.
-
Shielded Living Therapeutics Cell for Rare Blood Disorders
Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s ...
By Sigilon Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Software Solutions for Researchers
Save 70% of your time and maximize the probability of success of your clinical study. Avoid common pitfalls by starting your cohort study, patient registry, observational data collection, or clinical trial on Jeeva eClinical cloud platform. Save over 70% of the effort involved in toggling between numerous tools, coordination between multiple channels of engagement between study team and participants, participants use their own mobile device, and study specific data governance. ...
By Jeeva Informatics Solutions Inc. based in Manassas, VIRGINIA (USA).
-
Potential breakthrough treatment option for Critical Limb Ischemia (CLI)
Our First DCGI Approved Stem Cell Product: Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI (Indian FDA) for manufacturing and marketing for the treatment of Critical Limb Ischemia (CLI). Stempeucel® product has been licensed to Cipla in India. Stempeutics is seeking partnership for further clinical development and commercialization of Stempeucel® for Global ...
By Stempeutics Research Pvt. Ltd. based in Bangalore, INDIA.
-
Potential Functional Cures for Patients with Chronic Diseases
For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in ...
By Sigilon Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Shielded Living Therapeutics Cell for Lysosomal Diseases
Lysosomal diseases are a group of rare, genetic metabolic diseases in which cellular waste products build up in the body. These disorders are generally progressive and there is no cure. Many lysosomal diseases have no FDA-approved ...
By Sigilon Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Shielded Living Therapeutics Cell for Diabetes
Type 1 diabetes is a common chronic disease, affecting millions of people throughout the world, in which the immune system attacks the body’s own pancreatic cells, stopping the production of insulin. Though it was previously considered a childhood disease, type 1 diabetes is known to affect people at every age, and it has no ...
By Sigilon Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Software Solutions for CRO Partners
CROs can differentiate their services to sponsors with the white-labeled Jeeva eClinical technology platform advantage. Maximize the probability of winning contracts with sponsors by differentiating your proposals with Jeeva eClinical cloud. Sponsors want to know how you can ensure faster patient recruitment and better retention compared to your peers. Jeeva can rapidly turnaround with a budget proposal and branded material for inclusion in your response to sponsor RFPs and support you throughout the ...
By Jeeva Informatics Solutions Inc. based in Manassas, VIRGINIA (USA).
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you